Kala Pharmaceuticals has submitted an IND application to the FDA to initiate a Phase III program with its Mucus Penetrating Particle (MPP)-formulated loteprednol etabonate ophthalmic nano-suspension product (LE-MPP) for the treatment of post-operative inflammation and pain following cataract surgery. Kala’s proprietary MPP technology platform allows therapeutic agents to pass through the mucus layer of the ocular surface, facilitating penetration into deeper tissues of the eye, including the aq...